financetom
Economy
financetom
/
Economy
/
GST council to consider exemption of cancer drug from IGST
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GST council to consider exemption of cancer drug from IGST
Jul 7, 2023 8:52 AM

The GST Council at its next meeting on Tuesday, July 11, is likely to exempt cancer medicine Dinutuximab from tax. The drug, branded as Qarziba, is used to treat Neuroblastoma, a cancer of nerve cells in patients over 1 year of age.

Share Market Live

NSE

The drug worth Rs 36 lakh, is imported by individuals for personal use. It is currently taxed as at rate of 12 percent IGST. Opinion is that the medicine should be exempted from GST as the drug is expensive and money to fund treatment is generally through crowdfunding.

The parliamentary panel, last year, recommended waiving GST on cancer drugs. The panel pointed out that cancer treatment is expensive in the country and should be a notifiable disease. That means, it is required by law and information is reported to the government.

Experts point out that when it comes to patented or rare disease drugs, majority of the time the drugs are imported. Patient generally have to raise the funds on their own unless they are part of a charity program. Patients generally resort to crowd funding and donations. This is piecemeal as patients don’t always manage to raise funds.

The other option is filing a PIL to try and have the government support the patient via its rare diseases fund. While many of the times these options are effective, the process can run into months and many a times the administering of the drug is time sensitive.

Besides being expensive access to many of these rare disease and patented drugs is also unregulated and erratic. They are mostly imported that too on a need basis. Generally, when a drug is prescribed by a doctor, the patient is connected to either an NGO that helps facilitate the process or other patients that need the drug. The end goal, being a distributor, will import the drug generally for a group of patients.

Lawyers say pharma companies want to steer clear of manufacturing cheaper copies in the country due to the heavy patenting hence possibility of litigation.

The issue, experts say, has to be taken up at a government level to improve accessibility and options to reduce pricing such as compulsory licensing, raising the government funds for rare diseases and urging companies to adopt patients via CSR programs. ​

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Global equity funds see strong weekly inflows on U.S. rate cut hopes
Global equity funds see strong weekly inflows on U.S. rate cut hopes
May 24, 2024
(Reuters) - Global equity funds secured robust inflows in the week ended May 22, driven by optimism over slowing inflation and expectations of U.S. Federal Reserve rate cuts in the latter half of the year. According to Lipper data, global equity funds attracted $11.1 billion in inflows, a 22% increase from the previous week. U.S. equity funds received most of...
Analysis-Rising US debt burden spooks some bond investors ahead of November election
Analysis-Rising US debt burden spooks some bond investors ahead of November election
May 24, 2024
NEW YORK (Reuters) - Investors are bracing for a flood of U.S. government debt issuance that over time could dwarf an expected rally in bonds, as they see no end in sight for large fiscal deficits ahead of this year's presidential election. While bond markets so far this year have been driven mostly by bets on how deeply the Federal...
US Dollar Falls Widely in Europe as 'High Beta' FX Outperform
US Dollar Falls Widely in Europe as 'High Beta' FX Outperform
May 24, 2024
06:48 AM EDT, 05/24/2024 (MT Newswires) -- The US dollar fell against most major currencies in early European trade on Friday as 'high beta' counterparts outperformed despite weakness in some risky asset prices and a broad bid for government bonds. Most major currencies rose against the US dollar with the Swiss franc and Japanese yen the only exceptions in the...
Central bankers should acknowledge blind spots in a less certain world, Fed's Mester says
Central bankers should acknowledge blind spots in a less certain world, Fed's Mester says
May 24, 2024
AMELIA ISLAND, Florida (Reuters) - In nearly 40 years working for and helping lead the Federal Reserve, Cleveland Fed President Loretta Mester was part of a revolution that saw the U.S. central bank offer ever more detailed and plentiful commentary on the economy and monetary policy. As she heads towards mandatory retirement in June, the Cleveland Fed chief has a...
Copyright 2023-2025 - www.financetom.com All Rights Reserved